NHS National Generic Pharmaceuticals Wave 13

Tender Close: 26th July 2021, 13:00.
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)
CESW: 1 March 2022 – 30 September 2023 (19 months)
LSNE: 1 March 2022 – 31 January 2023 (11 months)
NWLN: 1 March 2022 – 31 January 2023 (11 months)

Oral Products plus non-parenterals
All Regions: 1 March 2022 – 31 May 2024 (27 months)

Hospital Only Products
CESW: 1 February 2022 – 30 September 2023 (20 months)
LSNE: 1 February 2022 – 31 May 2024 (28 months)
NWLN: 1 February 2022 – 31 January 2023 (12 months)